• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    11/14/24 1:46:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCEL alert in real time by email
    SC 13G/A 1 fp0090934-9_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 7)*

     

    Vericel Corporation

     

    (Name of Issuer)

     

    Common Stock, No Par Value Per Share

     

    (Title of Class of Securities)

     

    92346J108

     

    (CUSIP Number)

     

    Eddie C. Brown

    Brown Capital Management, LLC

    1201 N. Calvert Street

    Baltimore, MD 21202

    (410) 837-3234

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    September 30, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x] Rule 13d-1(b)

    [  ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
    CUSIP No. 92346J108   13G   Page 2 of 6 Pages
    1.

    NAMES OF REPORTING PERSONS 

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Brown Capital Management, LLC 

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (see instructions)

     

    (a) [  ] 

    (b) [  ]

     

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    State of Maryland 

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    2,120,669 

    6.

    SHARED VOTING POWER

     

    None 

    7.

    SOLE DISPOSITIVE POWER

     

    3,826,058 

    8.

    SHARED DISPOSITIVE POWER

     

    None 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,826,058 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

    (see instructions) [  ] 

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.80% 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     

     

     

    CUSIP No. 92346J108   13G   Page 3 of 6 Pages
    1.

    NAMES OF REPORTING PERSONS 

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    The Brown Capital Management Small Company Fund 

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (see instructions)

     

    (a) [  ] 

    (b) [  ]

     

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    State of Delaware 

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    1,517,190 

    6.

    SHARED VOTING POWER

     

    None 

    7.

    SOLE DISPOSITIVE POWER

     

    1,517,190 

    8.

    SHARED DISPOSITIVE POWER

     

    None 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,517,190 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

    (see instructions) [  ] 

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.09% 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IV 

     

     

     

    CUSIP No. 92346J108   13G   Page 4 of 6 Pages

     

    Item 1. (a)

    Name of Issuer 

    Vericel Corporation 

         
      (b)

    Address of Issuer’s Principal Executive Offices 

    64 Sidney Street 

    Cambridge, MA 02139 

     

    Item 2. (a)

    Name of Person Filing 

    Brown Capital Management, LLC 

    The Brown Capital Management Small Company Fund 

         
      (b)

    Address of the Principal Office or, if none, residence 

    1201 N. Calvert Street 

    Baltimore, MD 21202 

         
      (c)

    Citizenship 

    Brown Capital Management, LLC is a Maryland Limited Liability Company 

    The Brown Capital Management Small Company Fund is a series portfolio of Brown Capital Management Mutual Funds, a Delaware statutory trust 

         
      (d)

    Title of Class of Securities 

    Common Stock, No Par Value Per Share 

         
      (e)

    CUSIP Number 

    92346J108 

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [x] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 92346J108   13G   Page 5 of 6 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

        Brown Capital
    Management,
    LLC
    The Brown
    Capital Mgmt
    Small Company
    Fund
    (a) Amount beneficially owned: 3,826,058 1,517,190
    (b) Percent of class: 7.80% 3.09%
    (c) Number of shares as to which the person has:    
      (i) Sole power to vote or to direct the vote: 2,120,669 1,517,190
      (ii) Shared power to vote or to direct the vote: None None
      (iii) Sole power to dispose or to direct the disposition of: 3,826,058 1,517,190
      (iv) Shared power to dispose or to direct the disposition of: None None

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the shares of Common Stock set forth in Item 4 are owned by various investment advisory clients of Brown Capital Management, LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to it discretionary power to make investment decisions over such shares for its clients and/or its ability to vote such shares. In all cases, persons other than Brown Capital Management, LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares. No individual client holds more than five percent of the class, other than the Brown Capital Management Small Company Fund as disclosed in this filing.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     
     
    CUSIP No. 92346J108   13G   Page 6 of 6 Pages

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Brown Capital Management, LLC  
           
      By: /s/ Eddie C. Brown  
      Name: Eddie C. Brown  
      Title: CEO  
           
      Date: November 12, 2024  

    Get the next $VCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCEL

    DatePrice TargetRatingAnalyst
    9/17/2025Buy → Neutral
    BTIG Research
    8/9/2024$57.00Buy
    Canaccord Genuity
    6/20/2024$55.00Buy
    TD Cowen
    1/25/2024$39.00 → $51.00Hold → Buy
    Truist
    8/8/2023$39.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    11/9/2022Buy → Hold
    Truist
    10/14/2022$40.00Overweight
    Stephens
    More analyst ratings

    $VCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

    Issued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient's own living tissue behind.On May 21, 2026, a new Nasdaq ticker put a public-mark

    5/22/26 11:30:00 AM ET
    $AXGN
    $DDD
    $ESTA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

    Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 Revenue Guidance Raised by $10 Million to $326 to $336 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Total net revenue growth of 30% to $68.4 millionMACI®

    5/7/26 7:45:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

    CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be availab

    4/23/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    SEC Filings

    View All

    Vericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Vericel Corp (0000887359) (Filer)

    5/18/26 4:05:30 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Vericel Corporation

    10-Q - Vericel Corp (0000887359) (Filer)

    5/7/26 8:54:07 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vericel Corp (0000887359) (Filer)

    5/7/26 7:57:40 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hopper Jonathan Mark exercised 4,375 shares at a strike of $16.66 and sold $153,125 worth of shares (4,375 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    6/4/26 4:05:24 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    5/15/26 4:06:59 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    5/13/26 4:05:15 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vericel downgraded by BTIG Research

    BTIG Research downgraded Vericel from Buy to Neutral

    9/17/25 7:57:35 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Canaccord Genuity initiated coverage on Vericel with a new price target

    Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00

    8/9/24 8:07:19 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Vericel with a new price target

    TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00

    6/20/24 7:39:49 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 1:46:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 6:19:59 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    10/18/24 12:21:30 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

    CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and

    7/22/24 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

    Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie

    6/27/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

    New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,

    1/5/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Financials

    Live finance-specific insights

    View All

    Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

    Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 Revenue Guidance Raised by $10 Million to $326 to $336 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Total net revenue growth of 30% to $68.4 millionMACI®

    5/7/26 7:45:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

    CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be availab

    4/23/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

    Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Total net revenue growth of 23% to $92.9 millionMACI® net

    2/26/26 7:55:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care